About Epsilen Bio
Epsilen Bio is a company based in Milano (Italy) founded in 2019 by Angelo Lombardo and Luigi Naldini was acquired by Chroma Medicine in November 2021. Epsilen Bio offers products and services including Epigenetic Silencing. Epsilen Bio operates in a competitive market with competitors including Chroma Medicine, Bluepha, FOXO Technologies, Reaction Biology and Chronomics, among others.
- Headquarter Milano, Italy
- Founders Angelo Lombardo, Luigi Naldini
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
Not available
-
Investors
Chroma Medicine
& 1 more
-
Employee Count
Not available
-
Acquired by
Chroma Medicine
(Nov 17, 2021)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Epsilen Bio
Epsilen Bio offers a comprehensive portfolio of products and services, including Epigenetic Silencing.
Method to treat human diseases via epigenetic techniques.
People of Epsilen Bio
Unlock access to complete
Unlock access to complete
Funding Insights of Epsilen Bio
Investors in Epsilen Bio
Epsilen Bio has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Chroma Medicine and Sofinnova Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Locked | Locked | Locked | |
|
Epigenetic editing platform is developed for genomic medicines.
|
Locked | Locked | Locked |
Investor details for Epsilen Bio
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Epsilen Bio
Investment portfolio details for Epsilen Bio
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Epsilen Bio
Detailed financials for Epsilen Bio
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Epsilen Bio Comparisons
Peer comparison for Epsilen Bio
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Epsilen Bio
Epsilen Bio operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Chroma Medicine, Bluepha, FOXO Technologies, Reaction Biology and Chronomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Epigenetic editing platform is developed for genomic medicines.
|
|
| Locked | Locked | Locked |
Microbial manufacturing for bio-based products is developed.
|
|
| Locked | Locked | Locked |
Epigenetic biomarkers are discovered and developed via AI platforms.
|
|
| Locked | Locked | Locked |
In vitro enzyme activity assays, secializing in kinase & epigenetic HTS and profiling
|
|
| Locked | Locked | Locked |
Proactive healthcare analysis is enabled by DNA-based epigenetic tests.
|
|
| Locked | Locked | Locked |
Biomedical company offering DNA/RNA purification kits and NGS services for research.
|
Detailed competitors of Epsilen Bio
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Epsilen Bio
Complete news archive for Epsilen Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Epsilen Bio
Epsilen Bio was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Epsilen Bio is headquartered in Milano, Italy.
Julia Berretta is the current CEO of Epsilen Bio.
Founded in 2019 in Milano, Italy, Epsilen Bio operates in the biotechnology sector, where therapies are developed using Epigenetic Transcriptional Repressors (ETRs) for gene silencing. These approaches target inherited genetic diseases, cancer, autoimmune conditions, degenerative disorders, and viral infections. Operations focus on advancing clinical applications through innovative epigenetic mechanisms, with leadership provided by co-founders Angelo Lombardo and Luigi Naldini, alongside CEO Julia Berretta.
Epsilen Bio's top competitors include Chroma Medicine, FOXO Technologies and Bluepha.
Epsilen Bio offers Epigenetic Silencing.
Epsilen Bio has 2 investors. Key investors include Chroma Medicine, and Sofinnova Partners.